ArticleCardiovascular diagnosis and therapy2026
Drug-coated balloons (DCB) for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracranial atherosclerosis is a major cause of ischemic stroke, with high restenosis rates following angioplasty and stenting. Drug-coated balloons (DCBs) offer a potential alternative by delivering antiproliferative drugs to reduce restenosis. This systematic review and meta-analysis aimed to evaluate the restenosis rate and effectiveness of DCBs in treating intracranial atherosclerosis. Methods: PubMed, EMBASE, and Cochrane CENTRAL were searched from inception to April 13, 2025 (date of search). Eligible studies included randomized trials, and prospective and retrospective cohort studies evaluating DCBs in patients with symptomatic intracranial atherosclerosis. The primary outcomes were restenosis rate and degree of stenosis post-DCB treatment. Pooled proportions and odds ratios (ORs) with 95% confidence interval (CI) were calculated. Heterogeneity was assessed using the I Results: Twenty-six studies involving 1,489 patients were included. The pooled restenosis rate after DCB treatment was 11% (95% CI: 9-13%; I Conclusions: Restenosis rates following DCB treatment appear low and may be lower than those observed with non-DCB treatments in comparative studies. However, given the substantial heterogeneity in stenosis-related outcomes and the predominance of retrospective cohort studies, these findings should be interpreted cautiously. High-quality prospective studies, ideally randomized controlled trials, are warranted to better establish the long-term efficacy of DCB treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.